Fludarabine-based combined chemotherapy in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma;

Research progress on pharmacokinetics of fludarabine and its synergistic effect with cytarabine;

Effects of inhaled fludarabine to viral pneumonia in mice;

A process for the production of fludarabine and fludarabine phosphate was provided, wherein the guanosine was employed as the starting material,which is subjected to conversion of the 6-keto and 2-amino group to 6-amino and 2-fluoro group respectively, and conversion of ribofuranosyl moiety to arabinofuranosyl moiety .

All patients were treated with intravenous fludarabine at a dose of 25mg/m~2 per day for 5 days or with fludarabine-based chemotherapy regimens(FM: fludarabine 25 mg/m~2/d for three days, mitoxantrone 10 mg/m~2/d on day one; FMD: FM plus dexamethasone.

Synthesis of new anti-tumor drug fludarabine phosphate;

Fludarabine combined with colony-stimulating factor and cytarabine regimen for treatment of refractory or relapsed acute myeloid leukemia;

Clinical observation of fludarabine\mitoxantrone\dexamethasone in refractory low-degree malignant lymphoma;